Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the ...

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2-overexpressing cancers. The FDA has approved the 420-mg strength of the ...

Herceptin (trastuzumab) are similar in terms of efficacy, safety, and quality. The studies included two Phase 1 comparative single-dose pharmacokinetic (PK) studies conducted in healthy volunteers ...

Perspective from Stephanie Graff, MD The randomized phase 3 DESTINY-Breast03 trial compared the two antibody-drug conjugates for patients whose disease progressed after trastuzumab (Herceptin ...

Herceptin (trastuzumab) is a prescription drug that’s used to treat certain types of breast cancer and stomach cancer. Herceptin can cause side effects that range from mild to serious.